10,859 Shares in Clearside Biomedical Inc (CLSD) Purchased by MetLife Investment Advisors LLC

MetLife Investment Advisors LLC purchased a new position in shares of Clearside Biomedical Inc (NASDAQ:CLSD) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,859 shares of the company’s stock, valued at approximately $117,000.

Several other institutional investors have also recently modified their holdings of CLSD. Deutsche Bank AG increased its stake in shares of Clearside Biomedical by 33.8% during the fourth quarter. Deutsche Bank AG now owns 47,523 shares of the company’s stock worth $331,000 after acquiring an additional 12,012 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Clearside Biomedical by 29.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 47,378 shares of the company’s stock worth $332,000 after acquiring an additional 10,707 shares during the period. Paloma Partners Management Co acquired a new position in shares of Clearside Biomedical during the fourth quarter worth about $124,000. Millennium Management LLC acquired a new position in shares of Clearside Biomedical during the fourth quarter worth about $178,000. Finally, Northern Trust Corp increased its stake in shares of Clearside Biomedical by 8.7% during the first quarter. Northern Trust Corp now owns 243,398 shares of the company’s stock worth $2,611,000 after acquiring an additional 19,476 shares during the period. Institutional investors and hedge funds own 61.48% of the company’s stock.

Get Clearside Biomedical alerts:

In related news, Director Clay Thorp sold 161,139 shares of the business’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $13.08, for a total transaction of $2,107,698.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Daniel H. White purchased 11,000 shares of Clearside Biomedical stock in a transaction on Monday, June 4th. The stock was acquired at an average cost of $9.07 per share, for a total transaction of $99,770.00. Following the acquisition, the insider now directly owns 472,335 shares of the company’s stock, valued at $4,284,078.45. The disclosure for this purchase can be found here. 15.40% of the stock is currently owned by insiders.

A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. JMP Securities set a $25.00 price target on shares of Clearside Biomedical and gave the stock a “buy” rating in a research note on Saturday, June 9th. Janney Montgomery Scott assumed coverage on shares of Clearside Biomedical in a research note on Thursday. They set a “buy” rating on the stock. BidaskClub lowered shares of Clearside Biomedical from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Finally, Wedbush reiterated an “outperform” rating and set a $29.00 price target on shares of Clearside Biomedical in a research note on Friday, May 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $20.80.

CLSD stock opened at $10.69 on Friday. Clearside Biomedical Inc has a 52 week low of $5.30 and a 52 week high of $15.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.46 and a quick ratio of 7.46.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). Clearside Biomedical had a negative return on equity of 131.37% and a negative net margin of 17,094.20%. analysts expect that Clearside Biomedical Inc will post -2.39 earnings per share for the current fiscal year.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Want to see what other hedge funds are holding CLSD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clearside Biomedical Inc (NASDAQ:CLSD).